Immunogenicity, safety and tolerability of meningococcal C CRM197 conjugate vaccine administered 3, 5 and 11 months post-natally to pre- and full-term infants

Susanna Esposito, Barbara Corbellini, Samantha Bosis, Lorenza Pugni, Elena Tremolati, Claudia Tagliabue, Daniela Toneatto, Fabio Mosca, Nicola Principi

Research output: Contribution to journalArticle

Abstract

A total of 79 pre-term infants with a gestational age ≥32 weeks and 74 full-term infants were studied in order to evaluate the immunogenicity, safety and tolerability of meningococcal C (MenC)-CRM197 conjugate vaccine administered 3, 5 and 11 months post-natally. The evoked immune response seemed to be substantially similar in the pre- and full-term infants, and there were only clinically marginal differences in safety and tolerability between the groups. The results support the use of two doses of MenC-CRM197 vaccine at 3 and 5 months of age for primary immunisation, with a booster dose being given at about 1 year. In addition to reducing costs, this scheme seems to assure global immunogenicity and potential efficacy that is better than that offered by the accelerated scheme of administration with only three doses of vaccine in the first months of life, and similar to that observed with a fourth dose used as booster after the first year.

Original languageEnglish
Pages (from-to)4889-4894
Number of pages6
JournalVaccine
Volume25
Issue number26
DOIs
Publication statusPublished - Jun 21 2007

Keywords

  • Meningococcal C conjugate vaccine
  • Neisseria meningitidis
  • Pre-term infants

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Fingerprint Dive into the research topics of 'Immunogenicity, safety and tolerability of meningococcal C CRM197 conjugate vaccine administered 3, 5 and 11 months post-natally to pre- and full-term infants'. Together they form a unique fingerprint.

  • Cite this